A case of non-regenerative immune-mediated anemia treated by combination therapy of human immune globulin and mycophenolate mofetil in a dog

M. Yuki*  
Yuki Animal Hospital, 2-99 Kiba-cho, Minato-ku, Nagoya, Aichi 455-0021, Japan

Abstract
A 12-year-old female Shih Tzu dog was referred with diarrhea. Hematological examination indicated severe non-regenerative anemia. Bone marrow aspiration smears and core biopsy specimens revealed normal bone marrow. Based on those results, non-regenerative immune-mediated anemia was diagnosed. The dog was initially treated using prednisolone and cyclosporine. However, this treatment regimen did not prove effective. Nevertheless, the patient achieved a good hematological response after the administration of a combination therapy of human immune globulin and mycophenolate mofetil. Such a combination therapy may prove effective against non-regenerative immune-mediated anemia.

Keywords: Dog, Human immune globulin, Mycophenolate mofetil, Non-regenerative immune-mediated anemia

Introduction
Non-regenerative immune-mediated anemia (NRIMA) characterized by reticulocytopenia is considered uncommon in dogs (Scott-Moncrieff et al., 1995). NRIMA forms of immune-mediated hemolytic anemia have been hypothesized to be due to similar immunopathologic processes, in which an antibody is directed against red blood cell precursor antigens and mature red blood cell membrane antigens in their non-regenerative form (Jonas et al., 1987). Anti-erythrocyte antibody production may be a primary or secondary effect of viral infection, drug administration, vaccination, neoplasia, or blood transfusion (Duval and Giger, 1996). Treatment for NRIMA in dogs relies on corticosteroids and immunosuppressive drugs such as cyclophosphamide and azathioprine (Scott-Moncrieff et al., 1995; Stokol et al., 2000). In addition, some dogs that failed to respond to the above treatment have responded to other drug combinations, including cyclosporine and human intravenous immune globulin (hIVIG) (Scott-Moncrieff et al., 1995; Stokol et al., 2000).

Mycophenolate mofetil (MMF) is an immunosuppressive drug proven effective in reducing allograft rejection in human renal transplantation (Halloran, 1997). In recent clinical reports in humans, MMF has been shown to be useful in the treatment of many hematological disorders (Howard et al., 2002; Lin et al., 2002; Alba et al., 2003; Hou et al., 2003; Gan et al., 2005; Zhang et al., 2005).

In this case report, a dog with NRIMA was presented in which a good hematological response was achieved after an administration of MMF with hIVIG, and such a response suggests a possible role for this agent in the disease.

Case Details
A 12-year-old female Shih Tzu dog was referred with a three-day history of diarrhea. The dog had been vaccinated one week earlier with a combination vaccine (Duramune MX8, Kyoritsuseiyaku, Tokyo, Japan), and had been vaccinated every year so far. There were no special medical history, and no abnormal value was observed in a previous blood analysis.

A physical examination revealed a pale membrane. No additional abnormality was detected during the physical examination. Laboratory data at the time of admission indicated severe non-regenerative anemia (packed cell volume (PCV) 18%; reference range, 37 to 55%) with low reticulocyte counts (9.28×10^6/L; reference range, > 60×10^6/L), a moderate decrease in platelet counts (100×10^9/L; reference range, 200 to 500×10^9/L), mild elevations of both aspartate aminotransferase (97 U/L; reference range, 23-89 U/L) and blood urea nitrogen (25.4 mg/dL; reference range, 9.0-23.0 mg/dL), as well as increased levels of C-reactive protein (100 mg/L; reference range, 0-10 mg/L).

Mean cell volume and mean corpuscular hemoglobin concentration were normal, indicating normocytic normochromic anemia. The appropriate coagulation tests proved normal. Autoagglutination, a Coombs’ test and an antinuclear antibody test yielded negative results; urinalysis was normal. Abdominal radiography and ultrasonography revealed mild splenomegaly, characterized by homogeneous echogenicity.

Treatment every 12 h with ampicillin (20 mg/kg, SC) and prednisolone (1 mg/kg, SC) began on day 1. On day 3, non-regenerative anemia (PCV 14%, reticulocyte count were 5.73×10^6/L) had not improved.

*Corresponding Author: Masashi Yuki, Yuki Animal Hospital, 2-99 Kiba-cho, Minato-ku, Nagoya, Aichi 455-0021, Japan.  
Tel.: +81-52-694-1125, Fax: +81-52-694-5011. Email: yuki-masashi@mvf.biglobe.ne.jp
Bone marrow aspirate smears revealed a small number of erythrophagocytosis cases, but core biopsy specimens revealed normal bone marrow. The erythropoietin levels (66.4 mIU/mL; reference range, 7-37 mIU/mL) and serum iron levels (246 μg/dL; reference range, 30-180 μg/dL) were increased. On the basis of these findings, NRIMA was diagnosed. Administrations of oral cyclosporine (5 mg/kg, PO, every 12 h) commenced.

On day 10, there was still no improvement in the non-regenerative anemia (PCV 12%, in either the reticulocyte count of 9.78×10^9/L or the platelet count of 167×10^9/L) (Figure 1). Administration of MMF (10 mg/kg, PO, every 12 h) began. On day 12, a whole blood transfusion and hIVIG (0.5 g/kg, IV, as a 12-h infusion) were administered. By day 13, PCV had increased to 26%. On day 22, PCV (39%) and the reticulocyte count (84.78 ×10^9/L) continued to recover (Figure 1).

Due to the elevation of both hepatic enzyme activities and alanine aminotransferase (274 U/L; reference range, 29-84 U/L) and the alkaline phosphatase (1808 U/L; reference range, 62-150 U/L), the dose of prednisolone was gradually decreased. On day 27, however, both PCV (33%) and the reticulocyte count (26.52×10^9/L) had again declined (Figure 1), but PCV had recovered to 39% by day 34. PCV, hepatic enzyme activities and alkaline phosphatase had returned to normal by day 56 (Figure 1).

**Discussion**

In the present case, thrombocytopenia, which is commonly observed together with immune-mediated hemolytic anemia in dogs (Klag et al., 1993; Mitchell and Kruth, 2010), was detected in conjunction with NRIMA. In one retrospective study, 26% of the dogs with a diagnosis of immune-mediated hemolytic anemia had been vaccinated within four weeks of diagnosis (Duval and Giger, 1996).

This case had been vaccinated one week earlier with a combination vaccine. However, this case was diagnosed as NRIMA. Thus, considering the half-life of erythrocytes in dogs, the case seems unrelated to a vaccine.

Hypercellularity, erythroid hyperplasia and myelofibrosis are usually observed in the bone marrow of NRIMA patients (Scott-Moncrieff et al., 1995; Stokol et al., 2000; Weiss, 2006). On the other hand, there is no pathognomonic finding on bone marrow biopsy. Bone marrow plasma cell hyperplasia or lymphocytosis supports the diagnosis, but its absence does not rule it out (Abrams-Ogg, 2010).

No clear abnormality was observed by marrow aspirate smears in this case. However, the diagnosis was NRIMA because of the small number of erythrophagocytosis cases observed by bone marrow aspirate smears.

![Fig. 1 Clinical course of treatment with prednisolone, cyclosporine, human intravenous immune globulin and mycophenolate mofetil in a dog with non-regenerative immune-mediated anemia.](http://www.openveterinaryjournal.com)
hIVIG has been shown to be of some benefit in
immune-mediated hemolytic anemia in human
patients who are refractory to conventional treatment
(Flores et al., 1993).
A blockade of Fc receptors on mononuclear
phagocytic cells has been proposed as the most likely
mechanism accounting for the rapid, early response to
hIVIG treatment (Scott-Moncrieff et al., 1995). It has
long-term effects, since the half-life of hIVIG in
humans is 18 to 32 days. However, in dogs, it is much
shorter (seven to nine days (Scott-Moncrieff et al.,
1997)).
MMF is metabolized to mycophenolic acid, which
inhibits 5’-inosine monophosphate dehydrogenase, a
critical enzyme in the de novo synthesis of purine
nucleotides. MMF suppresses both B- and T-
lymphocyte proliferation, autoantibody production,
and the glycosylation of adhesion molecules (Allison
and Eugui, 1996; Hood and Zarembski, 1997).
In recent clinical reports in humans, MMF has been
shown to be useful in the treatment of many
hematological disorders, such as autoimmune
hemolytic anemia, idiopathic thrombocytopenic
purpura and aplastic anemia (Howard et al., 2002; Lin
et al., 2002; Alba et al., 2003; Hou et al., 2003; Gan et
al., 2005; Zhang et al., 2005). Moreover, its use for
the treatment of aplastic anemia has also been tried in
veterinary medicine (Yuki et al., 2007).
The major adverse effects of MMF in humans include
diarrhea, vomiting, dysuria, leucopenia and anemia.
Since such effects are usually reversible and transient
(Hood and Zarembski, 1997), they did not appear in
the present case. In a clinical report of a human patient
with autoimmune hemolytic anemia treated using
MMF, the recovery of hemoglobin levels took about
one month, indicating that MMF is a slow-acting drug
(Lin et al., 2002). In addition, in a prior case of
 aplastic anemia (Yuki et al., 2007), it took MMF
about three weeks to take effect, as with azathioprine
(Jergens, 1999).
Our present case was initially treated with
prednisolone and cyclosporine, a regimen that failed
to prove effective. Next, a medication with the slow-
acting drug mycophenolate mofetil was planned, but a
transitional medicine was first needed until the effect
of the mycophenolate mofetil was revealed. As a
result, when human immune globulin was administered, it combined smoothly with the
mycophenolate mofetil.
It seemed that a decrease in PCV on day 27 had
negated the effect of hIVIG, which indicated that
prednisolone and cyclosporine were ineffective.
However, since this was a period during which MMF
begins to take effect, PCV increased again, and
complete remission was obtained.

In conclusion, MMF may prove effective against
NRIMA, and hIVIG medication appeared effective
until MMF took effect.

References
Textbook of veterinary internal medicine, Eds.,
Ettinger, S. J. and Feldman, E. C. Philadelphia,
W.B. Saunders, pp.788-797.
Mycophenolate mofetil as a treatment for
autoimmune haemolytic anemia in patients with
systemic lupus erythematosus and
antiphospholipid syndrome. Lupus. 12, 633-635.
metabolism and immunosuppressive effects of
mycophenolate mofetil. Clin. Transplant. 10, 77-
84.
immune-mediated hemolytic anemia in the dog. J.
Flores, G., Cunningham-Rundles, C., Newland, A.C.
and Bussel, J.B. 1993. Efficacy of intravenous
immunoglobulin in the treatment of autoimmune
hemolytic anemia: results in 73 patients. Am. J.
Gan, G.G., Leong, C.F., Sangkar, J.V., Teh, A., Goh,
mycophenolate mofetil in treating patients with
non responding aplastic anemia. Med. J. Malaysia
60, 311-313.
allograft recipients: a pooled efficacy analysis of
three randomized, double-blind, clinical studies in
prevention of rejection. The international
mycophenolate mofetil renal transplant study
groups. Transplantation 63, 39-47.
Mycophenolate mofetil: a unique
immunosuppressive agent. Am. J. Health Syst.
Pharm. 54, 285-294.
Hou, M., Peng, J., Shi, Y., Zhang, C., Qin, P., Zhao,
Mycophenolate mofetil (MMF) for the treatment of
steroid-resistant idiopathic thrombocytopenic
Howard, J., Hoffbrand, A.V., Prentice, H.G. and
Mehta, A. 2002. Mycophenolate mofetil for the
treatment of refractory auto-immune haemolytic
anemia and auto-immune thrombocytopenia
Nonregenerative form of immune-mediated